Q1 2026 · 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLCholdings as filed
Filed 2026-05-14 · accession 0001420506-26-001011
$979.8M
Reported value
73
Positions
2026-03-31
Period end
The Brief · SILVERARC CAPITAL MANAGEMENT, LLC · Q1 2026
AI · grounded in 13F
SILVERARC CAPITAL MANAGEMENT, LLC established a new position in SPDR SERIES TRUST valued at $105.4M. The fund also opened a new position in ZBIO for $22.2M and increased its stake in ASNDUSD by 153.2%. On the sell side, the fund closed positions in VRDN, PFE, and AVTX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78464A950 | — | SPDR SERIES TRUST | $105.4M | 10.8% | 825,000 | PUT | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $57.9M | 5.91% | 2,876,407 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $54.9M | 5.61% | 654,746 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $50.6M | 5.16% | 1,314,189 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $40.9M | 4.17% | 357,903 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $40.5M | 4.13% | 1,850,278 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $37.8M | 3.86% | 991,930 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $36.4M | 3.71% | 354,914 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $33.7M | 3.44% | 302,530 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $32.9M | 3.36% | 2,002,040 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $30.0M | 3.06% | 1,851,812 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $28.5M | 2.91% | 124,658 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $27.0M | 2.76% | 1,503,045 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $26.6M | 2.72% | 306,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $23.1M | 2.35% | 71,552 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $22.2M | 2.27% | 1,135,935 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $20.8M | 2.12% | 888,987 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $18.5M | 1.89% | 466,345 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $16.7M | 1.70% | 339,613 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $16.3M | 1.66% | 460,314 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $13.9M | 1.42% | 1,100,010 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $12.5M | 1.28% | 196,028 | Common | SOLE |
| G4444S107 | HLXC | HELIX ACQUISITION CORP III | $12.3M | 1.25% | 1,208,986 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $11.5M | 1.17% | 197,759 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $11.3M | 1.15% | 166,349 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $10.3M | 1.05% | 414,236 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $9.4M | 0.96% | 186,618 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $9.3M | 0.95% | 50,967 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $9.1M | 0.93% | 98,514 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $8.4M | 0.86% | 144,981 | Common | SOLE |
| N90064901 | QURE | UNIQURE NV | $8.2M | 0.83% | 500,000 | CALL | SOLE |
| 805111101 | SVRA | SAVARA INC | $7.8M | 0.80% | 1,430,982 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $7.6M | 0.78% | 717,725 | Common | SOLE |
| 87164F905 | SNDX | SYNDAX PHARMACEUTICALS INC | $7.5M | 0.76% | 320,000 | CALL | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $7.4M | 0.76% | 150,908 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $7.1M | 0.72% | 3,315,845 | Common | SOLE |
| 15102K900 | CELC | CELCUITY INC | $6.2M | 0.63% | 54,500 | CALL | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $6.1M | 0.62% | 511,127 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $5.9M | 0.60% | 35,850 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $5.8M | 0.59% | 179,700 | Common | SOLE |
| 157085101 | CERS | CERUS CORP | $5.8M | 0.59% | 3,176,547 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $5.7M | 0.58% | 178,378 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $5.0M | 0.51% | 1,911,785 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $4.7M | 0.48% | 71,203 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $4.7M | 0.48% | 684,908 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $4.5M | 0.46% | 859,049 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $4.2M | 0.43% | 144,255 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $3.9M | 0.40% | 301,729 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $3.3M | 0.34% | 560,651 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $3.2M | 0.33% | 419,949 | Common | SOLE |
| 359616909 | FULC | FULCRUM THERAPEUTICS INC | $3.0M | 0.31% | 391,900 | CALL | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $2.9M | 0.30% | 648,942 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $2.9M | 0.29% | 653,594 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $2.8M | 0.28% | 496,461 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $2.6M | 0.27% | 2,498,020 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $2.4M | 0.24% | 130,500 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $2.4M | 0.24% | 43,488 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $2.2M | 0.23% | 1,000,000 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $1.9M | 0.19% | 176,057 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.7M | 0.17% | 300,000 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $1.6M | 0.16% | 818,156 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $1.6M | 0.16% | 39,417 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $1.4M | 0.14% | 2,259,312 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $1.3M | 0.14% | 42,615 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $1.3M | 0.13% | 171,936 | Common | SOLE |
| 370920100 | GENB | GENERATE BIOMEDICINES INC | $1.3M | 0.13% | 100,000 | Common | SOLE |
| 20454B904 | CMPX | COMPASS THERAPEUTICS INC | $911,996 | 0.09% | 172,400 | CALL | SOLE |
| 75041J101 | RADX | RADIOPHARM THERANOSTICS LTD | $805,846 | 0.08% | 187,406 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $779,004 | 0.08% | 1,701,625 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $429,400 | 0.04% | 226,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $289,768 | 0.03% | 251,972 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $126,989 | 0.01% | 33,684 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $2,159 | 0.00% | 104,828 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.